Neuphoria Therapeutics (NEUP) Competitors $8.10 +0.15 (+1.89%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock NEUP vs. ANL, VRCA, ZIVO, IFRX, LTRN, HOWL, PYRGF, UNCY, PDSB, and ADVMShould you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include Adlai Nortye (ANL), Verrica Pharmaceuticals (VRCA), ZIVO Bioscience (ZIVO), InflaRx (IFRX), Lantern Pharma (LTRN), Werewolf Therapeutics (HOWL), PyroGenesis Canada (PYRGF), Unicycive Therapeutics (UNCY), PDS Biotechnology (PDSB), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics vs. Its Competitors Adlai Nortye Verrica Pharmaceuticals ZIVO Bioscience InflaRx Lantern Pharma Werewolf Therapeutics PyroGenesis Canada Unicycive Therapeutics PDS Biotechnology Adverum Biotechnologies Adlai Nortye (NASDAQ:ANL) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Do insiders and institutionals believe in ANL or NEUP? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 0.7% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer ANL or NEUP? In the previous week, Adlai Nortye had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Adlai Nortye and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Adlai Nortye's score of 0.29 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Neutral Neuphoria Therapeutics Very Positive Do analysts rate ANL or NEUP? Adlai Nortye currently has a consensus price target of $9.00, indicating a potential upside of 411.36%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 159.26%. Given Adlai Nortye's higher probable upside, equities analysts plainly believe Adlai Nortye is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, ANL or NEUP? Neuphoria Therapeutics has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M12.99-$51.87MN/AN/ANeuphoria Therapeutics$10K1,522.80-$15.49MN/AN/A Is ANL or NEUP more profitable? Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Neuphoria Therapeutics N/A N/A N/A Which has more volatility and risk, ANL or NEUP? Adlai Nortye has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. SummaryNeuphoria Therapeutics beats Adlai Nortye on 7 of the 11 factors compared between the two stocks. Get Neuphoria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.95M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / Sales1,522.80356.37470.66115.79Price / CashN/A43.0338.2159.48Price / Book0.518.608.846.15Net Income-$15.49M-$54.65M$3.25B$265.06M7 Day Performance9.02%5.86%3.72%2.60%1 Month Performance7.14%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.23%25.58% Neuphoria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics2.316 of 5 stars$8.10+1.9%$21.00+159.3%N/A$14.95M$10K0.00N/APositive NewsANLAdlai Nortye1.3767 of 5 stars$1.58+1.6%$9.00+471.4%-46.7%$57.19M$5M0.00127Short Interest ↑Gap DownVRCAVerrica Pharmaceuticals4.5955 of 5 stars$6.35+3.9%$80.00+1,159.8%-80.3%$56.51M$7.57M-0.5340Earnings ReportShort Interest ↓ZIVOZIVO Bioscience0.2562 of 5 stars$14.49flatN/A+112.4%$55.31M$15.85K-2.9710News CoverageIFRXInflaRx3.2576 of 5 stars$0.80-1.8%$6.60+724.8%-38.7%$54.72M$180K-1.0060Gap DownLTRNLantern Pharma2.7136 of 5 stars$4.99flat$25.00+401.0%+16.0%$53.82MN/A-2.7120Earnings ReportGap UpHOWLWerewolf Therapeutics3.7308 of 5 stars$1.17-0.8%$8.33+612.3%-33.7%$52.95M$1.88M-0.7040News CoverageEarnings ReportPYRGFPyroGenesis CanadaN/A$0.28-0.2%N/A-55.0%$52.45M$9.14M-4.6790High Trading VolumeUNCYUnicycive Therapeutics2.669 of 5 stars$4.09+0.7%$60.00+1,367.0%+46.4%$51.32M$680K-0.809News CoverageEarnings ReportGap DownPDSBPDS Biotechnology2.0818 of 5 stars$1.11-0.9%$9.00+710.8%-60.3%$51.19MN/A-1.1820News CoverageEarnings ReportADVMAdverum Biotechnologies3.9366 of 5 stars$2.29-6.5%$23.80+939.3%-57.1%$51.18M$1M-0.36190News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies ANL Competitors VRCA Competitors ZIVO Competitors IFRX Competitors LTRN Competitors HOWL Competitors PYRGF Competitors UNCY Competitors PDSB Competitors ADVM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access